# Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

> **NCT01145495** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 66 (actual)

## Conditions studied

- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage III Grade 3 Follicular Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Grade 3 Follicular Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01145495
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-15
- **Primary completion:** 2012-12-31
- **Final completion:** 2022-01-15
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145495, "Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01145495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*